Business
Haemonetics Gains Analyst Backing After Strategic Vivasure Buyout
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.